4 receptors: fgfr1-4 22 ligands: fgf1-23
DESCRIPTION
9. MECHANISMS OF DEVELOPMENT I – REGULATION OF LIMB DEVELOPMENT BY FIBROBLAST GROWTH FACTORS (FGF). 4 receptors: FGFR1-4 22 ligands: FGF1-23. Fgf10 -/-. Fgf10 -/-. wt. wt. AER. Fgf8/Fgf4 -/-. Fgf8/Fgf4 -/-. wt. wt. How do the limbs grow?. age. resting cartilage. - PowerPoint PPT PresentationTRANSCRIPT
9. MECHANISMS OF DEVELOPMENT I – REGULATION OF LIMB DEVELOPMENT BY FIBROBLAST GROWTH
FACTORS (FGF)
4 receptors: FGFR1-422 ligands: FGF1-23
wt Fgf10-/-
AER
wt Fgf10-/-
Fgf8/Fgf4-/-wt Fgf8/Fgf4-/-wt
How do the limbs grow?
resting cartilage
bone
proliferating cartilage
proliferating cartilage
age
resting cartilage
FGFR3
Fgfr3+/-
Fgfr3+/-
Fgfr3-/-
Tail
Fgfr3-/-
FGFR3-related skeletal dysplasia
HypochondroplasiaAchondroplasiaSADDANThanatophoric Dysplasia
STATURE AC
TM
TK
I
II
III
FGF binds here
FGFR3-related skeletal dysplasia
Achondroplasia
Thanatophoric Dysplasia
- short long bones
- brachydactyly
- macrocephaly
- low nasal bridge
- spinal stenosis
- temporal lobe malformations
healthy
TD
Fgfr3+/-
Loss-of-function vs. Gain-of-function
Fgfr3-/-
Fgfr3+/+
Fgfr3TD/+
healthy TD
resting
proliferating
hypertrophic
bone
0.01 0.1 1 10 1000
5e+4
1e+5
2e+5
2e+5FGF1 FGF1 + HeparinFGF2FGF9ControlHeparin
3H-thymidine (cpm x 103)
0 10 20 30 400
20
40
60
80
100
G0-G1SG2-M
FGF2 (h)
% of cells
FGF concentration (ng/ml)
FGFR3 inhibits chondrocyte proliferation by arresting
their cell cycle in G1 phase
….via inhibition of cdk activity necessary for progression through the G1 phase of a cell cycle
control FGF
FGF alters the cartilage-like phenotype of chondrocytes
FGF (h)
- 0.5 1 4 8 12 24 48 72
aggrecan
collagen II
collagen I
GAPDH
proMMP2
……via MMP-mediated degradation of extracellular matrix
MMP2
MMP3
MMP9
MMP10
MMP13
GAPDH
con
trol
FG
F2
proMMP9 matureMMP9
intermediate matureMMP2
proMMP13 matureMMP13
con
trol
FG
F2
proMMP2
mature MMP3/10
pro MMP3/10
FGF2 activates Erk and p38 MAPK, PLC and PKB in chondrocytes
C1 C2 1’ 5’ 10’ 30’ 1h 2h 4h 8h
FGF2
P-Erk1/2
Erk1/2
P-p38
p38
P-PLC1
PLC1
P-PKB
PKB
1’ 5’ 30’ 1h 4h 6h 12h 18h 24h 0h 4h 12hF F/H F F/H F F/H F F/H F F/H F F/H F F/H F F/H F F/H - - H - H
0.001 0.01 0.1 1 10 100
0
20
40
60
80
.001 .01 .1 1 10 100Inhibitor concentration (M)
U0126
cells/wellx103
0
2
4
6
8
10
12
1 2
- U0126
RasV12
cells/wellx103
cells/wellx103
0
20
40
60
80
control f1 f10 f100
Series1Series2
cell colonies/100 cells (%)
RasRasN17
0.001 0.01 0.1 1 10 100
0
20
40
60
80
FGF2control
SU5402
……but only Ras/Erk activity is involved in FGF-induced growth arrest
80
60
40
20
0
80
60
40
20
0
- F1 F10 F100
Erk MAP kinase activity is necessary for
FGFR3 phenotype in cartilage
FGFR3
Ras
Raf-1
MEK
Erk
FRS2
FGF2
C-type Natriuretic Peptide (CNP) over-expression results in skeleton overgrowth in mice
CNP
wild-type
CNP over-expression??? CNPwild-type
wild-type
Fgfr3Ach
Fgfr3Ach/CNP
CNP rescues dwarfism caused by ACH mutation in FGFR3
Series2
Series3
control
FGF2
FGF2
control
_ 0.1 0.2 0.5 1 _ _ _ _ CNP [M] _ _ _ _ _ 10 100 200 500 pCPT-cGMP [M]
50
40
30
20
10
0
cells
per
wel
l [x1
04]
CNP counteracts FGF2-mediated chondrocyte growth arrest through cGMP-dependent pathway
CNP antagonizes FGF2-mediated loss of cartilage extracellular matrix in chondrocytes
control
CNP
pCPT-cGMP
unstimulated FGF2
CNP counteracts FGF2-mediated activation of Erk MAP kinase in chondrocytes
_ + + + + _ _ + + + + _ FGF2 _ _ 0.1 0.2 0.5 0.1 _ _ _ _ _ _ CNP [M] _ _ _ _ _ _ _ _ 100 200 500 100 pCPT-cGMP [M]
Erk1/2
P-Erk1/2
Ras total
Ras-GST
FGF2 _ + + _
CNP _ _ + +
Erk1/2
P-Erk1/2
FGF2 _ + + _
CNP _ _ + + _Ab
Erk1/2
Raf-1 IP: Raf-1
WB P-MEK
P-Erk1/2
FGFR3
Ras
Raf-1
MEK
Erk
FRS2
FGF2
CNP inhibits Erk MAP kinase module at the Raf level
FGFR3
Ras
CNP
cGMP
PKG Raf-1
MEK
Erk
NP-R FRS2
STOP
FGF2
Growth arrest
Matrix degradation
Is protein kinase C (PKC) involved in FGFR3- mediated activation of Erk in chondrocytes?
FGF2 _ + + + + _ + + + _ _ + + + + _
Gö6983 (M) _ _ 1 5 10 5 _ _ _ _ _ _ _ _ _ _
Bis I (M) _ _ _ _ _ _ 1 5 10 5 _ _ _ _ _ _
Gö6976 (M) _ _ _ _ _ _ _ _ _ _ _ _ 1 5 10 5
Erk2
P-Erk1/2
FGF2 _ + + + + + + + + _
GFX (M) _ _ 0.5 1 5 10 20 50 _ 10
vehicle (DMSO) _ _ + + + + + + + +
kinase
P-Elk
FGFR3
Ras
Raf-1
MEK
Erk
FRS2
FGF2
FRS2
FGFR3
-Y-FRS2P
FGF2 _ + + + + + + + + + +
Bis I (M) _ _ 1 5 10 20 50 _ _ _ _
SU5402(M) _ _ _ _ _ _ _ 1 10 20 _
vehicle(DMSO) _ _ + + + + + + + + +
kinase
Ras
Raf-1
MEK
Erk
FGF2
Gab1
SHP2GRB2SOS
GRB2SOS
FRS2
FGFR3
FGF2 _ 5’ 10’ 30’ 1h _ 30’ 30’ _
Bis I _ _ _ _ _ _ _ + + IP: FRS2
WB FRS2
SHP2
IP: Gab1
WB Gab1
SHP2
Protein kinase C inhibitor Bisindolylmaleimide I (Bis I)suppresses the FGF2-mediated activation of Erk MAP kinase pathway in
chondrocytes by preventing the SHP2 association with FRS2 and Gab1 adaptor proteins
FGFR3
Ras
Raf-1
MEK
Erk
FRS2
FGF2
Gab1
SHC
Grb2-SOSShp2-Grb2-SOS
Bis I Bis I
?
FGFR3 associates with STAT1 and acts as STAT1-kinase in chondrocytes
CKI
FGFR3
STAT1
Growth arrest
?
?
?
FLAG
actin
FLAG IP: FLAG
WB STAT1
FG
FR
3-w
t
FG
FR
3-K
650M
FG
FR
3-K
508M
GF
P
FGFR3-wt
substrate: STAT1 + + + + + +
SU5402(M) _ + _ _ + _
ATP + + _ + + _
FGFR3-K650E
P-Y701-STAT1
STAT1
FGFR3
Chronic FGF stimulus inhibits cytokine/STAT signaling in
chondrocytes
STAT3-YFP DAPI merge DIC/merge
control
IL6 30mFGF2 48h
FGF2 2h
IL6 30m
FGF2 48h
STAT3
STAT3-YFP
75
150kDa
100
IL11, LIF
CishSocs1Socs3
FGF2
IL6
IL6RA Shp2
gp130
STAT3
STAT3
nucleus
FGFR3
Frs2
Chronic FGF stimulus inhibits cytokine/STAT signaling in
chondrocytes
FGF2 causes premature senescence in chondrocytes
SA--gal
control FGF2 FGF2 [ng/ml] - 5 10 20
0
12
24
36
48
SA
--g
al p
osit
ive c
ells
per
50 c
ells [
n=
10]
FGF2 signals towards the cytoskeleton in chondrocytes
Phalloidin DAPI merge
control
FGF2
actin
FGF2: C1 15‘ 1h 3h 6h 12h 24h 48h 72h C2 C3
Wnt
b-catenin
Where is Wnt?
Frs2, Gab1, SHC
CKI
?
STAT1
Ras/Raf/MEK/Erk
STAT1
CKI MMP
PKC
CNP
NPR-B
cGMP
PKG
2001 2008 IL6, LIF, IL11, IFN
STAT1/3
growth arrest
growth arrest
matrix degradation
?
?
?
proliferation
SOCS1/3
FGFR3
FGFR3